Enhanced pharmacokinetic and therapeutic of GSH-responsive mPEG-b-P(HPMA)-SGI1776 conjugate for osteosarcoma
IntroductionSGI-1776 represents the first serine/threonine kinase inhibitor to be utilized in the treatment of osteosarcoma. It is severely restricted by poor aqueous solubility, short degradation half-life and severe side effect.MethodsA polymeric prodrug is prepared by covalently embedding SGI-177...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2025-10-01
|
| Serie: | Frontiers in Pharmacology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1676770/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|